Your Source for Venture Capital and Private Equity Financings

Arch Oncology Secures $105M Series C

2021-04-28
BRISBANE, CA, Arch Oncology has closed a $105M Series C financing co-led by Eventide Asset Management, Cowen Healthcare Investments and current investor 3x5 Partners.
Arch Oncology, a clinical-stage immuno-oncology, has closed a $105 million Series C financing co-led by Eventide Asset Management, Cowen Healthcare Investments and current investor 3x5 Partners, who were joined by new investors Adage Capital Management, Point72 Asset Management, Avego Healthcare Capital, FMB Research and Broadfin Holdings.

Arch Oncology's existing investors, including Roche Venture Fund, RiverVest Venture Partners, and Lightchain, also participated in the round.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors